Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · IEX Real-Time Price · USD
1.335
-0.015 (-1.11%)
Jul 22, 2024, 10:07 AM EDT - Market open
Akebia Therapeutics Employees
Akebia Therapeutics had 167 employees as of December 31, 2023. The number of employees decreased by 38 or -18.54% compared to the previous year.
Employees
167
Change (1Y)
-38
Growth (1Y)
-18.54%
Revenue / Employee
$1,121,108
Profits / Employee
-$257,677
Market Cap
285.05M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Accolade | 2,400 |
AngioDynamics | 815 |
MeiraGTx Holdings | 425 |
LifeMD | 211 |
Omeros | 198 |
Prelude Therapeutics | 128 |
Orchestra BioMed Holdings | 56 |
Artiva Biotherapeutics | 43 |
AKBA News
- 11 days ago - Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets - PRNewsWire
- 20 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 25 days ago - Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference - PRNewsWire
- 4 weeks ago - Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference - PRNewsWire
- 2 months ago - Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire
- 2 months ago - Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights - PRNewsWire